The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study

12Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Background: Lung cancer is one of the most common cancers worldwide. Patients with early stage lung cancer have improved long-term survival. With the introduction of low-dose CT scan, more patients are going to be diagnosed at an early stage. However, there is limited data on the risk of second primary malignancies (SPMs) in these subsets of patients in the United States. Methods: We utilized SEER-13 (Surveillance, Epidemiology and End Results) registry to obtain Multiple Primary- Standardized Incidence Ratio and an Absolute Excess Risk between January 2004 and December 2010 for patients with Stage Ia non-small cell lung cancer. Results: The database comprised of 12,246 patients. A total of 1431 (11.68%) patients developed 1563 SPMs with an observed to expected (O/E) ratio of 2.07 (95% CI = 1.92–2.23, p

Cite

CITATION STYLE

APA

Khanal, A., Lashari, B. H., Kruthiventi, S., Arjyal, L., Bista, A., Rimal, P., & Uprety, D. (2018). The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study. Acta Oncologica, 57(2), 239–243. https://doi.org/10.1080/0284186X.2017.1390250

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free